[PET in gliomas. Overview of current studies]
Related Experiment Video
Updated: Apr 29, 2026
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
Published on: December 28, 2017
1Prof. Dr. W.-D. Heiss, Max-Planck-Institut für neurologische Forschung, Gleueler Str. 50, 50931 Köln, Tel. 02 21/472 62 20, Fax 02 21/472 63 49,
Abstract:
Gliomas which represent 30% of intracranial tumours are morphologic lesions and therefore CT and MRI are the first line diagnostic procedures with MRI giving better soft tissue resolution and permitting additional functional information. These mainly morphologic imaging modalities yield only restricted information on grade of malignancy, on infiltration into and effects on surrounding brain tissue, on differentiation between necrotic and recurrent tumour, on prognosis and on efficacy of treatment. Information on these important issues for patient management can be obtained by PET-studies of glucose metabolism with FDG, of aminoacid-uptake and protein synthesis with 11C-methionin, 18F-fluorethyltyrosin and 18F-fluor-deoxyphenylalanin and of proliferation by 18F-deoxythymidin. With the increasing availability of 18F-tracers PET has obtained wider spread clinical application. In all these applications a coregistration with morphologic imaging should be obtained, and for that purpose hybrid installations (PET-MR) are already being used.
Insights
Positron Emission Tomography (PET) offers crucial insights beyond standard imaging for glioma patients. PET scans, particularly with advanced tracers, provide vital information on tumor grade, prognosis, and treatment response, improving patient management.
Area of Science:
- Neuro-oncology
- Medical Imaging
- Nuclear Medicine
Context:
- Gliomas are the most common primary brain tumors, accounting for 30% of intracranial neoplasms.
- Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are primary diagnostic tools, offering detailed morphological information.
- However, conventional imaging has limitations in assessing tumor grade, infiltration, prognosis, and treatment efficacy.
Purpose:
- To explore the role of Positron Emission Tomography (PET) in enhancing glioma diagnosis and management.
- To highlight the utility of various PET tracers for assessing metabolic activity, amino acid uptake, protein synthesis, and proliferation.
- To emphasize the importance of integrating PET findings with morphological imaging.
Summary:
- PET imaging, utilizing tracers like FDG, 11C-methionine, 18F-fluorethyltyrosine, 18F-fluor-deoxyphenylalanine, and 18F-deoxythymidine, provides critical functional and metabolic information about gliomas.
- These PET studies offer insights into glucose metabolism, amino acid uptake, protein synthesis, and cell proliferation, which are not fully captured by CT or MRI.
- The increasing availability of 18F-tracers is expanding the clinical applications of PET in neuro-oncology.
- Coregistration of PET with morphological imaging (CT/MRI) is essential for accurate interpretation, with hybrid PET-MRI systems facilitating this integration.
Impact:
- PET imaging significantly improves the assessment of glioma malignancy grade, tumor infiltration, and differentiation between tumor recurrence and necrosis.
- It provides valuable prognostic information and aids in monitoring treatment response, leading to more personalized patient management strategies.
- The integration of PET with advanced tracers and hybrid imaging technologies represents a significant advancement in the clinical management of glioma patients.
